HomeNew EGFR Inhibitors

New EGFR Inhibitors

Catalog No. Product Name Information
E6000 BIEGi-1 BIEGi-1 is a potent and selective binary inhibitor of EGFR that effectively blocks EGFR-catalyzed nucleotide exchange and disrupts the EGFR–Rheb interaction. It robustly inhibits both EGFR kinase activity and mTORC1 signaling in EGFR-mutant cancer cells. BIEGi-1 exhibits significant anti-proliferative effects with an IC50 of 17 nM for PC9 and 20 nM for HCC827.
F0053 EGF Receptor Rabbit mAb EGF Receptor,EGFR,Epidermal Growth Factor Receptor
E1919 Befotertinib mesylate Befotertinib mesylate (D-0316 mesylate) is third-generation tyrosine kinase inhibitor (TKI) of EGFR . It can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).
E5912 Asandeutertinib Asandeutertinib (Osimertinib-d3, AZD-9291-d3) is an orally administered, ATP-competitive, irreversible, deuterated third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) and a deuterium-stabilized derivative of osimertinib, with the potential to treat advanced EGFR-mutated NSCLC.
E5906 Sunvozertinib Sunvozertinib (DZD9008) is an oral, potent, and selective inhibitor of ErbBs (EGFR or Her2), particularly mutant forms of ErbBs. It also inhibits EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, Her2 exon 20 YVMA, and EGFR WT A431, with IC50 values of 20.4 nM, 20.4 nM, 1.1 nM, 7.5 nM, and 80.4 nM, respectively.
≡ All EGFR Inhibitors